Table 1.
Baseline characteristics in the as-treated population with high-intensity statins
| Rosuvastatin N = 948 |
Atorvastatin N = 856 |
P-value | |
|---|---|---|---|
| Age, mean (SD), years | 65 ± 9 | 65 ± 10 | 0.623 |
| Male | 675 (71) | 621 (73) | 0.526 |
| Female | 273 (29) | 235 (28) | 0.526 |
| Weight, mean (SD), kg | 66 ± 10 | 67 ± 10 | 0.500 |
| Height, mean (SD), cm | 164 ± 8 | 165 ± 8 | 0.418 |
| Body-mass index, mean (SD), kg/m2 | 24.6 (2.9) | 24.6 (2.8) | 0.953 |
| Past medical history | |||
| Hypertension | 600 (63) | 535 (63) | 0.728 |
| Chronic kidney disease | 34 (4) | 37 (4) | 0.422 |
| End-stage kidney disease on dialysis | 1 (< 1) | 1 (< 1) | 0.942 |
| Previous PCI | 511 (54) | 443 (52) | 0.361 |
| Previous CABG | 55 (6) | 46 (5) | 0.693 |
| Previous stroke | 39 (4) | 38 (4) | 0.733 |
| Current smoker | 135 (14) | 1119 (14) | 0.836 |
| Estimated GFR, mean (SD), ml/min/1.73 m2 | 90 ± 15 | 90 ± 15 | 0.989 |
| Lipids, mean (SD), mg/dL | |||
| Low-density lipoprotein cholesterol | 91 ± 31 | 92 ± 31 | 0.582 |
| High-density lipoprotein cholesterol | 48 ± 12 | 48 ± 11 | 0.656 |
| Total cholesterol | 163 ± 38 | 162 ± 36 | 0.462 |
| Triglycerides | 132 ± 72 | 132 ± 79 | 0.787 |
| Fasting glucose, mg/dL* | 0.031 | ||
| <99 | 381 (41) | 306 (37) | |
| 100–125 | 472 (51) | 435 (52) | |
| ≥126 | 75 (8) | 94 (11) | |
| Clinical presentation at randomization | 0.090 | ||
| Acute myocardial infarction within 1 year | 58 (6) | 78 (9) | |
| > 1 year after myocardial infarction | 121 (13) | 118 (14) | |
| Unstable angina or revascularization within 1 year | 182 (19) | 148 (17) | |
| >1 year after unstable angina or revascularization | 395 (42) | 329 (38) | |
| Detection of CAD at screening without symptoms | 192 (20) | 183 (21) | |
| Lipid lowering therapy before randomization | |||
| Statin† | 0.004 | ||
| High-intensity statin | 206 (22) | 245 (29) | |
| Moderate-intensity statin | 549 (58) | 465 (54) | |
| Low-intensity statin | 16 (2) | 8 (1) | |
| None | 177 (19) | 138 (16) | |
| Ezetimibe | 79 (8) | 58 (7) | 0.212 |
CABG = coronary-artery bypass grafting; CAD = coronary artery disease; GFR = glomerular filtration rate; PCI = percutaneous coronary intervention
* 20 patients in the rosuvastatin group and 21 patients in the atorvastatin group did not measure fasting glucose at baseline
† The intensity of statin treatment was divided according to the 2018 American College of Cardiology/American Heart Association guideline for the treatment of blood cholesterol